Head and Neck Cancer Clinical Trial
— SCV-07 OMOfficial title:
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SC-07 for the Delay to Onset of Severe Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck.
Verified date | December 2008 |
Source | SciClone Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug or
radiation regiments used to treat cancer. This study examines the investigational drug
SCV-07 and it's possible application in treating Oral Mucositis. Studies have shown that
SCV-07 can possibly increase a broad immune system response, thus lowering the painful side
effects experienced when treated for head and neck cancer.
The purpose of this study is to assess the safety and tolerability of SCV-07 and it's
ability to delay the onset of Oral Mucositis for patients receiving chemoradiation for head
and neck cancer.
Status | Completed |
Enrollment | 59 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject must have a body weight less than 150 kg at screening - Have recently-diagnosed, pathologically-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with chemoradiation therapy as first line treatment(postoperative patients are eligible, if surgery is < 6 weeks prior to initiation of radiotherapy. - Plan to receive a continuous course of conventional external beam irradiation - Plan to receive a standard cisplatin chemotherapy regimen Exclusion Criteria: - Pregnant or breastfeeding - Have head and neck tumors of the lips, sinuses, salivary glands or unknown primary tumor - Prior radiation to the head and neck - Have a plan to receive cetuximab (Erbitux) in conjunction with chemotherapy - Had curative surgery more than 6 weeks prior to the initiation of radiotherapy - Have current oral mucositis - Presence of active infectious disease excluding oral candidiasis - Chronic immunosuppression - Seropositive for HIV or hepatitis B surface antigen or C antibody - Used an investigational agent within 30 days of randomization - Have a known sensitivity to any investigational agent |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United States | St Luke's Hospital & Health Network | Bethlehem | Pennsylvania |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Mid Dakota Clinic | Bismarck | North Dakota |
United States | Montefiore Medical Center | Bronx | New York |
United States | Carolinas Medical Center | Charlotte | North Carolina |
United States | University of Illinois at Chicago | Chicago | Illinois |
United States | Ohio State University Medical Center | Columbis | Ohio |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | James Graham Brown Cancer Center | Lousiville | Kentucky |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee |
United States | Beth Israel Medical Center | New York | New York |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Whittingham Cancer Center | Norwalk | Connecticut |
United States | The Nebraska Medical Center | Omaha | Nebraska |
United States | Temple University | Philadelphia | Pennsylvania |
United States | Arizona Oncology Services Foundation | Phoenix | Arizona |
United States | Washington University in St Louis | St Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
SciClone Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety will be assessed by collecting and recording AEs and laboratory assessments. Labs will be collected at screening,weekly throughout the subject's RT treatment and on the last day of radiotherapy. | 7 Weeks | Yes | |
Primary | Efficacy of Oral Mucositis assessment will be completed by trained site personnel. The WHO score will be the primary measure and NCI CTCAE will be a secondary measure for assessing Oral Mucositis. | 7 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |